The Philadelphia chromosome (Ph) is generated by a balanced reciprocal translocation t(9;22)(q34;q11.2), in which the ABL1 and BCR genes are disrupted to form a BCR-ABL1 fusion gene. In most patients with chronic myeloid leukemia (CML), and in approximately one-third of patients with Ph-positive acute lymphoblastic leukemia (ALL), the breakpoint within the BCR gene is located in the major breakpoint cluster region (M-bcr), leading to formation of e13a2 (b2a2) or e14a2 (b3a2) fusion transcripts encoding a p210 BCRÀABL1 fusion protein.
In the remaining patients with Ph-positive ALL, and in a few patients with CML, the breakpoint is located in the minor breakpoint cluster region, thereby resulting in production of the e1a2 fusion transcript and p190 BCRÀABL1 fusion protein. A very rare breakpoint is located distally to the M-bcr region between exons 19 and 20, defined as the micro breakpoint cluster region, which produces an e19a2 fusion transcript encoding a p230 BCRÀABL1 fusion protein. The e19a2 transcript was initially reported in neutrophilic-CML patients with benign clinical courses. However, this finding has subsequently been challenged by the observation that the e19a2 transcript was also present in all stages of classical CML and in acute myeloid leukemia. [1] [2] [3] [4] Here, to the best of our knowledge, we report on the first case of Ph-positive ALL with the e19a2 transcript at presentation. The patient showed hematological and cytogenetic complete remission (CR) with a reduction in BCR-ABL1 transcript level after imatinib plus conventional chemotherapy, and, subsequently, achieved molecular CR after matched unrelated donor transplantation.
In August 2009, a 24-year-old woman presented with exertional dyspnea and splenomegaly. Peripheral blood findings were as follows: hemoglobin 7.9 g/dl, white blood cells 33.1 Â 10 9 /l (blasts 80%, segmented neutrophils 11%, lymphocytes 5%, monocytes 4%) and platelets 49.0 Â 10 9 /l. Bone marrow examination showed 98% blasts that were positive for CD10, CD19, CD20, cy-CD22, CD79a, HLA-DR and CD34, indicating a precursor B-lineage ALL. Cytogenetic analysis of bone marrow cells showed 45,XX,der(9)del(9) (p22)t(9;22)(q34;q11.2),-13,der(22)t(9;22) in 28/30 metaphases analyzed ( Figure 1a) . A multiplex PCR method (HemaVision, DNA Technology A/S, Aarhus, Denmark) was used for detection of the e19a2 transcript ( Figure 1b ). For assessment of molecular response, real-time quantitative PCR was also performed as previously reported. 5 The patient was diagnosed with Ph-positive ALL with the e19a2 transcript and promptly received imatinib in combination with conventional chemotherapy, as previously reported. 5 As shown in Figure 2 , after the first 4 weeks of imatinib therapy (400 mg/day) following induction chemotherapy (hyperfractionated cyclophosphamide, vincristine, idarubicin and dexamethasone), she achieved hematological and cytogenetic CR with a reduction in the BCR-ABL1 transcript level (À2.45 log) from baseline value. After the second cycle of imatinib therapy following consolidation chemotherapy (high-dose cytarabine and mitoxantrone), she showed sustained hematological and cytogenetic CR with a further reduction in the BCR-ABL1 transcript level (À3.08 log) from baseline value. In December 2009, she underwent myeloablative conditioning (total body irradiation (13.2 Gy) þ cyclophosphamide (120 mg/kg)) and peripheral blood stem cell transplantation from a matched unrelated donor. Tacrolimus (0.03 mg/kg/day, intravenously, from day À1) plus methotrexate (10 mg/m 2 , intravenously, on days 1, 3, 6 and 11) was administered for prophylaxis of graft-versushost disease. On day 21 post-transplant, she showed successful engraftment with an undetectable BCR-ABL1 transcript. At present, 9 months after transplantation, the patient has sustained hematological, cytogenetic and molecular CR of her disease.
To date, on searching the literature, additional chromosomal abnormalities (for example, þ 8, double Ph, i(17q)) have been observed at presentation in 13 out of less than 50 patients with Letters to the Editor the e19a2 transcript. These abnormalities were associated with less favorable clinical courses, with a median survival probability projected at 37 or 190 months for those with or without additional abnormalities, respectively. 3, 4 Furthermore, some of these cases presented initially as CML in transformation or as acute myeloid leukemia. Our case also had an additional chromosomal abnormality (del(9)(p22), À13) at the time of diagnosis. These reports and our case suggest that the presence of the e19a2 transcript, especially in cases showing additional chromosomal abnormalities, might be associated with presentation of more aggressive phenotypes or disease progression.
According to the few available reports on imatinib treatment in CML patients with the e19a2 transcript, imatinib induces hematological, cytogenetic or molecular responses. 4, 6 Previously, we also reported that imatinib could induce complete cytogenetic response in three CML patients with the e19a2 transcript (two chronic phases, one myeloid blastic crisis). 6 In the present case, imatinib in combination with conventional chemotherapy served as a good bridge to unrelated donor transplantation in terms of hematological, cytogenetic and molecular responses. These reports and our case suggest that imatinib may be valuable for e19a2-positive CML as well as Ph-positive ALL. Some recent case reports have suggested that the emergence of a BCR-ABL1 kinase domain mutation (for example, Y253H, E355G) induces imatinib resistance in e19a2-positive CML patients. 7, 8 Thus, more studies are warranted in order to further illustrate the influence of the e19a2 transcript on clinical features at presentation, progression of the disease and response to imatinib therapy.
Activation of a novel palmitoyltransferase ZDHHC14 in acute biphenotypic leukemia and subsets of acute myeloid leukemia The current World Health Organization (WHO) classification of hematological malignancies includes a number of entities defined by specific genetic abnormalities. Most known abnormalities result from chromosomal translocations and mutations involving genes encoding transcription factors or tyrosine kinases. We report here the finding of activation of a novel palmitoyltransferase ZDHHC14 through the chromosomal 
